Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
January 23 2024 - 4:00PM
Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”)
(Nasdaq: ESPR) announced today the closing of its previously
announced underwritten public offering of 65,205,000 shares of its
common stock, including 8,505,000 shares of its common stock
pursuant to the underwriters’ exercise in full of their option to
purchase additional shares of common stock, at the public offering
price of $1.50 per share. The gross proceeds from the offering,
before deducting underwriting discounts and commissions and other
offering expenses payable by Esperion, are approximately $97.8
million.
Jefferies LLC acted as sole book-running manager
for the offering.
Esperion intends to use the net proceeds from
the offering of common stock, together with its existing cash and
cash equivalents, to fund the ongoing commercialization efforts for
NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and
ezetimibe), research and clinical development of current or
additional pipeline candidates, working capital, capital
expenditures, and general corporate purposes.
A registration statement relating to the
offering of common stock has been filed with the Securities and
Exchange Commission (“SEC”) and was declared effective on April 26,
2022. A final prospectus supplement and accompanying prospectus
relating to and describing the terms of the offering was filed with
the SEC on January 22, 2024. Copies of the final prospectus
supplement and the accompanying prospectus may be obtained on the
SEC’s website at http://www.sec.gov or by contacting Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, New York 10022, by telephone at 877-821-7388, or
by email at prospectus_department@jefferies.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any offer or sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Esperion Therapeutics
At Esperion, we discover, develop, and
commercialize innovative medicines to help improve outcomes for
patients with or at risk for cardiovascular and cardiometabolic
diseases. We are focused on developing and commercializing
accessible, oral, once-daily, non-statin medicines for patients
struggling with elevated low-density lipoprotein cholesterol, or
LDL-C. Through commercial execution and completion of our global
cardiovascular outcomes trial as well as advancing our pre-clinical
pipeline, we continue to evolve into a differentiated, global
cardiometabolic biotech.
Special Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws, including, without limitation,
statements related to the intended use of proceeds from the public
offering. These statements involve risks, uncertainties and other
factors that may cause actual results, levels of activity,
performance, or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this press release, we
caution you that these statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. We cannot assure you that
the forward-looking statements in this press release will prove to
be accurate. Furthermore, if the forward-looking statements prove
to be inaccurate, the inaccuracy may be material. Actual
performance and results may differ materially from those projected
or suggested in the forward-looking statements due to various risks
and uncertainties, including the risks detailed in Esperion’s
filings with the SEC, including in our most recent Annual Report on
Form 10-K and in subsequent filings with the SEC. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Esperion disclaims any obligation
or undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by law.
Contact
Investors:Alexis Callahan Investorrelations@esperion.com(406)
539-1762
Media:Tiffany Aldrichcorporateteam@esperion.com(616)
443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024